# Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Canonical URL: https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-pricing-of-upsized-120-million-public-offering-5606c6d1
Ticker: CMPX
Company: Compass Therapeutics
Source: Compass Therapeutics
Published: 2025-08-13 02:28 EST
## Summary

Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.

## Article Body
Compass Therapeutics, Inc. (“Compass”) (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the pricing of an underwritten public offering of 33,290,000 shares of its common stock at a price to the public of $3.00 per share and pre-funded warrants to purchase up to an aggregate of 6,710,000 shares of its common stock at a price to the public of $2.9999 per pre-funded warrant to purchase one share of the common stock, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. The gross proceeds from the offering to Compass are expected to be approximately $120 million, before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about August 14, 2025, subject to customary closing conditions. In addition, Compass has granted the underwriters a 30-day option to purchase up to 6,000,000 additional shares of common stock at the public offering price, less the underwriting discount.
## Recent Company News
- 2026-07-17 14:42 EST — [Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026](https://biopharmsignal.com/news/CMPX/compass-therapeutics-announces-tovecimig-data-accepted-for-an-oral-presentation--350ddb60) — Source: Compass Therapeutics
- 2026-05-28 11:30 EST — [Compass Therapeutics to Participate in Upcoming June Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-june-investor-events-1eb21840) — Source: Compass Therapeutics
- 2026-05-21 21:00 EST — [Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-present-promising-phase-1-clinical-data-for-ctx-8371-in--211bb911) — Source: Compass Therapeutics
- 2026-05-12 11:30 EST — [Compass Therapeutics to Participate in Upcoming May Investor Events](https://biopharmsignal.com/news/CMPX/compass-therapeutics-to-participate-in-upcoming-may-investor-events-a79d8121) — Source: Compass Therapeutics
- 2026-05-05 11:30 EST — [Compass Therapeutics Reports 2026 First Quarter Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CMPX/compass-therapeutics-reports-2026-first-quarter-financial-results-and-provides-c-7bfdf19a) — Source: Compass Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)